Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $649

Benzinga Newsdesk www.benzinga.com Negative 95.3%

Neg 95.3% Neu 0% Pos 0%

Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and lowers the price target from $652 to $649.